Organon/OGN

$21.85

0.36%
-
1D1W1MYTD1YMAX

About Organon

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Ticker

OGN

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Kevin Ali

Employees

10,000

Headquarters

Jersey city, United States

Organon Metrics

BasicAdvanced
$5.6B
Market cap
5.35
P/E ratio
$4.08
EPS
-
Beta
$1.12
Dividend rate
5.14%
Dividend yield
$5.6B
$24.08
$10.84
2.2M
$1.12
1.649
1.152
18,135.42
18,154.17
27.98%
18.352
2.36%
9.24%
11.79%
5.346
0.883
116.197
25.6
5.14%
5.14%
3.29%
39.6%
-1.39%
-23.49%

What the Analysts think about Organon

Analyst Ratings

Majority rating from 10 analysts.
Hold

Price Targets

Average projection from 8 analysts.
2.97% upside
High $30.00
Low $16.00
$21.85
Current price
$22.50
Average price target

Organon Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
12.39% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.6B
1.5%
Net income
$201M
-63.19%
Profit margin
12.39%
-63.73%

Organon Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25.69%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.31
$0.87
$0.88
$1.22
-
Expected
$1.01
$1.06
$0.83
$0.97
$1.17
Surprise
30.13%
-17.66%
6.02%
25.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Organon stock?

Organon (OGN) has a market cap of $5.6B as of May 22, 2024.

What is the P/E ratio for Organon stock?

The price to earnings (P/E) ratio for Organon (OGN) stock is 5.35 as of May 22, 2024.

Does Organon stock pay dividends?

Yes, the Organon (OGN) stock pays dividends to shareholders. As of May 22, 2024, the dividend rate is $1.12 and the yield is 5.14%. Organon has a payout ratio of 27.98% on a trailing twelve-month basis.

When is the next Organon dividend payment date?

The next Organon (OGN) dividend payment is scheduled for June 13, 2024.

What is the beta indicator for Organon?

Organon (OGN) does not currently have a Beta indicator.

What is the Organon stock price target?

The target price for Organon (OGN) stock is $22.5, which is 2.97% above the current price of $21.85. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Organon stock

Buy or sell Organon stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing